Go Pro
→ The comeback story of the century (ticker inside) (From InvestorPlace) (Ad)tc pixel Free ATHE Stock Alerts

Alterity Therapeutics (ATHE) Financials

Alterity Therapeutics logo
$4.54 -0.15 (-3.20%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$4.60 +0.06 (+1.39%)
As of 07/24/2026 07:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Alterity Therapeutics

Annual Income Statements for Alterity Therapeutics

This table shows Alterity Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 -5.80 -5.80 -6.13 -8.59 -9.31 -12 -8.87 -9.20 -13 -7.98
Consolidated Net Income / (Loss)		 -5.80 -5.80 -6.13 -8.59 -9.31 -12 -8.87 -9.20 -13 -7.98
Net Income / (Loss) Continuing Operations		 -5.80 -5.80 -6.13 -8.59 -9.31 -12 -8.87 -9.20 -13 -7.98
Total Pre-Tax Income 		-5.80 -5.80 -6.13 -8.59 -9.31 -12 -8.82 -9.13 -13 -7.94
Total Operating Income		 -10 -7.71 -8.39 -12 -9.63 -15 -14 -12 -16 -13
Total Gross Profit		 -0.07 -0.19 -0.17 -0.22 -0.24 -0.22 -0.25 -0.18 -0.14 -0.08
Total Revenue		 0.11 0.00 0.00 0.00 0.01 0.05 0.00 0.01 0.00 0.00
Operating Revenue		 0.11 - 0.00 0.00 0.01 0.05 0.00 0.01 0.00 0.00
Total Cost of Revenue		 0.18 0.19 0.17 0.22 0.24 0.27 0.25 0.19 0.14 0.08
Operating Cost of Revenue		 0.18 0.19 0.17 0.22 0.24 0.27 0.25 0.19 0.14 0.08
Total Operating Expenses		 9.93 7.53 8.23 12 9.40 14 14 12 16 13
Selling, General & Admin Expense		 2.71 3.05 3.22 3.00 2.38 5.21 3.81 3.37 3.18 3.60
Research & Development Expense		 7.19 4.38 4.97 9.04 6.98 9.23 10 8.79 12 9.47
Other Operating Expenses / (Income)		 0.03 0.10 0.04 0.09 0.03 0.00 0.00 0.02 0.00 0.06
Total Other Income / (Expense), net		 4.21 1.92 2.27 3.77 0.33 3.16 5.42 3.23 3.04 5.27
Interest Expense		 - - -0.15 -0.08 -0.01 -0.02 -0.00 -0.01 -0.18 -0.29
Other Income / (Expense), net		 4.21 1.82 2.12 3.69 0.32 3.15 5.42 3.22 2.86 4.98
Income Tax Expense		 - 0.00 0.00 0.00 0.00 0.00 0.05 0.07 0.03 0.04
Weighted Average Basic Shares Outstanding		 533.89M 533.89M 533.89M 615.77M 894.87M 1.70B 2.41B 2.43B 3.65B 6.40B
Diluted Earnings per Share		 ($1.45) ($1.41) ($1.55) ($2.00) ($1.50) - - ($0.38) ($0.35) ($0.12)
Weighted Average Diluted Shares Outstanding		 533.89M 533.89M 533.89M 615.77M 894.87M 1.70B 2.41B 2.43B 3.65B 9.13B
Weighted Average Basic & Diluted Shares Outstanding		 533.89M 533.89M 533.89M 615.77M 894.87M 1.70B 2.41B 2.44B 3.65B 6.40B
Cash Dividends to Common per Share		 - - - - - ($0.90) ($0.37) ($0.38) ($0.35) ($0.12)

Quarterly Income Statements for Alterity Therapeutics

No quarterly income statements for Alterity Therapeutics are available.

Annual Cash Flow Statements for Alterity Therapeutics

This table details how cash moves in and out of Alterity Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Net Change in Cash & Equivalents		 -5.57 -4.65 -4.72 -0.86 -3.78 29 2.68 -13 -2.27 14
Net Cash From Operating Activities		 -5.54 -4.51 -4.82 -0.94 -3.78 0.00 -9.38 -13 -2.39 -7.53
Net Cash From Continuing Operating Activities		 -5.54 0.11 -4.82 -0.94 -3.78 0.00 -9.38 -13 -2.39 0.25
Net Income / (Loss) Continuing Operations		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Changes in Operating Assets and Liabilities, net		 4.89 0.11 2.24 2.26 3.34 - 2.85 0.00 5.73 0.25
Net Cash From Investing Activities		 -0.00 -0.02 -0.05 -0.00 -0.01 29 -0.06 -0.00 -0.00 -4.93
Net Cash From Continuing Investing Activities		 -0.00 -0.02 -0.05 -0.00 -0.01 29 -0.06 -0.00 -0.00 -4.93
Purchase of Property, Plant & Equipment		 -0.00 -0.02 -0.05 - - - - - - 0.00
Sale and/or Maturity of Investments		 - - 0.00 - - 29 - - - -4.93
Net Cash From Financing Activities		 0.00 -0.12 0.00 0.00 0.00 0.00 12 0.00 0.00 26
Net Cash From Continuing Financing Activities		 0.00 -0.12 0.00 0.00 0.00 0.00 12 0.00 0.00 26
Repayment of Debt		 - - - - - - - - - -0.08
Repurchase of Common Equity		 - -0.12 - - - - - - - -1.82
Other Financing Activities, net		 - - - - - - - - - 28

Quarterly Cash Flow Statements for Alterity Therapeutics

No quarterly cash flow statements for Alterity Therapeutics are available.

Annual Balance Sheets for Alterity Therapeutics

This table presents Alterity Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Total Assets		 19 14 14 6.85 25 29 18 13 30
Total Current Assets		 19 14 14 6.80 25 28 18 13 30
Cash & Equivalents		 17 11 10 6.36 21 24 11 8.44 22
Accounts Receivable		 2.33 2.34 3.36 0.04 3.21 3.26 5.77 2.70 2.59
Other Current Assets		 0.25 0.20 0.44 0.40 0.82 1.11 1.74 1.57 5.77
Plant, Property, & Equipment, net		 0.02 0.05 0.03 0.03 0.02 0.07 0.04 0.02 0.00
Total Noncurrent Assets		 0.00 0.00 0.00 0.02 0.05 0.08 15 0.10 0.10
Noncurrent Note & Lease Receivables		 - - 0.00 0.02 0.05 0.08 - 0.10 0.10
Total Liabilities & Shareholders' Equity		 19 14 14 6.85 25 29 33 13 30
Total Liabilities		 1.22 1.96 2.34 1.91 2.34 4.07 3.00 3.62 2.38
Total Current Liabilities		 1.22 1.96 2.31 1.88 2.30 4.02 2.92 3.59 2.32
Accounts Payable		 0.69 1.52 1.89 1.43 1.88 3.51 2.34 3.08 1.69
Current Deferred & Payable Income Tax Liabilities		 - - - - 0.00 0.02 0.02 0.01 0.01
Other Current Liabilities		 0.54 0.44 0.42 0.45 0.42 0.49 0.56 0.49 0.62
Total Noncurrent Liabilities		 0.00 0.00 0.02 0.03 0.04 0.05 0.08 0.03 0.06
Other Noncurrent Operating Liabilities		 0.00 0.00 0.02 0.03 0.04 0.05 0.08 0.03 0.06
Total Equity & Noncontrolling Interests		 18 12 12 4.94 23 24 30 9.21 28
Total Preferred & Common Equity		 18 12 12 4.94 23 24 30 9.21 28
Total Common Equity		 18 12 12 4.94 23 24 30 9.21 28
Common Stock		 111 107 109 111 148 148 143 149 173
Retained Earnings		 -94 -96 -98 -107 -128 -126 -130 -143 -148
Other Equity Adjustments		 1.78 1.30 0.81 0.60 2.07 2.46 18 3.21 3.51

Quarterly Balance Sheets for Alterity Therapeutics

No quarterly balance sheets for Alterity Therapeutics are available.

Annual Metrics And Ratios for Alterity Therapeutics

This table displays calculated financial ratios and metrics derived from Alterity Therapeutics' official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
DEI Shares Outstanding		 0.00 0.00 533,891,470.00 860,837,432.00 1,037,358,032.00 2,084,016,678.00 2,406,874,578.00 2,439,897,618.00 5,245,115,318.00 5,245,115,318.00
DEI Adjusted Shares Outstanding		 0.00 0.00 53,389,147.00 86,083,743.00 103,735,803.00 208,401,668.00 240,687,458.00 2,439,897,618.00 5,245,115,318.00 5,245,115,318.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -0.11 -0.10 -0.09 -0.06 -0.04 0.00 0.00 0.00
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% -100.00% 0.00% 0.00% 0.00% 494.97% -100.00% 0.00% -100.00% 0.00%
EBITDA Growth		 0.00% -1.74% -6.40% -38.11% -7.48% -23.62% 23.38% -3.59% -41.32% 36.26%
EBIT Growth		 0.00% -1.74% -6.40% -38.11% -7.48% -23.62% 23.38% -3.59% -41.32% 36.26%
NOPAT Growth		 0.00% 22.91% -8.79% -47.27% 22.07% -52.24% 2.88% 13.20% -27.62% 16.25%
Net Income Growth		 0.00% 0.02% -5.70% -40.24% -8.29% -23.61% 22.88% -3.70% -38.80% 37.47%
EPS Growth		 0.00% 2.76% -9.93% -29.03% 25.00% 0.00% 0.00% 0.00% 8.58% 64.03%
Operating Cash Flow Growth		 0.00% 18.62% -7.01% 80.49% -301.42% 100.00% 0.00% -40.34% 81.83% -214.62%
Free Cash Flow Firm Growth		 0.00% 0.00% 24.65% -86.26% 59.83% -251.42% 35.63% -224.44% 128.75% -280.22%
Invested Capital Growth		 0.00% 0.00% -54.82% 139.42% -194.27% 225.05% -74.17% 4,252.69% -96.11% 685.08%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 -69.61% 0.00% 0.00% 0.00% -2,837.13% -447.15% 0.00% -1,562.20% 0.00% 0.00%
EBITDA Margin		 -5,418.28% 0.00% 0.00% 0.00% -112,134.00% -23,297.85% 0.00% -79,991.52% 0.00% 0.00%
Operating Margin		 -9,351.45% 0.00% 0.00% 0.00% -115,927.18% -29,662.75% 0.00% -108,178.12% 0.00% 0.00%
EBIT Margin		 -5,418.28% 0.00% 0.00% 0.00% -112,134.00% -23,297.85% 0.00% -79,991.52% 0.00% 0.00%
Profit (Net Income) Margin		 -5,418.28% 0.00% 0.00% 0.00% -111,991.54% -23,266.43% 0.00% -80,504.78% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.55% 100.76% 100.24% 100.56%
Interest Burden Percent		 100.00% 98.27% 97.62% 99.13% 99.87% 99.87% 99.98% 99.88% 98.61% 96.44%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% -15,691.95% -5,792.53% 0.00% -85.05% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% -15,660.67% -5,783.53% 0.00% -81.89% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 15,578.98% 5,709.89% 0.00% 51.54% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -31.84% -40.67% -73.28% -112.97% -82.64% -37.44% -33.52% -64.47% -43.06%
Cash Return on Invested Capital (CROIC)		 0.00% -978.45% -507.82% -895.44% 0.00% -760.14% -777.72% -276.07% 78.14% -424.82%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% -89.94% -71.80% 0.00% -39.09% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% -89.83% -71.70% 0.00% -39.34% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% -31.84% -40.67% -73.28% -112.97% -82.64% -37.44% -33.52% -64.47% -43.06%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -31.84% -51.40% -74.53% -188.19% -50.24% -36.22% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -7.00 -5.40 -5.88 -8.65 -6.74 -10 -9.97 -8.65 -11 -9.25
NOPAT Margin		 -6,546.01% 0.00% 0.00% 0.00% -81,149.02% -20,763.92% 0.00% -75,724.69% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -4.72% -1.80% 0.55% -31.27% -9.00% 4.87% -3.16% -18.22% 8.36%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -28.46% -119.86% -33.18%
Cost of Revenue to Revenue		 169.61% 0.00% 0.00% 0.00% 2,937.13% 547.15% 0.00% 1,662.20% 0.00% 0.00%
SG&A Expenses to Revenue		 2,530.93% 0.00% 0.00% 0.00% 28,679.81% 10,543.80% 0.00% 29,484.49% 0.00% 0.00%
R&D to Revenue		 6,719.17% 0.00% 0.00% 0.00% 84,042.26% 18,668.41% 0.00% 76,959.97% 0.00% 0.00%
Operating Expenses to Revenue		 9,281.84% 0.00% 0.00% 0.00% 113,090.05% 29,215.60% 0.00% 106,615.92% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -5.80 -5.90 -6.28 -8.67 -9.32 -12 -8.82 -9.14 -13 -8.23
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -5.80 -5.90 -6.28 -8.67 -9.32 -12 -8.82 -9.14 -13 -8.23
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 1.01 3.45 0.98 0.87 0.37 7.99 12.82
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 1.01 3.45 0.98 0.87 0.37 7.99 12.82
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 2,054.79 454.65 0.00 980.20 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 1.08 0.00 0.76 0.00 0.03 84.19 55.23
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 1,289.40 27.36 0.00 60.45 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 8.07 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -0.92 -0.93 -0.91 -0.99 -0.99 -0.95 -0.63 -0.48 -0.82
Leverage Ratio		 0.00 1.07 1.11 1.18 1.26 1.15 1.14 0.85 0.78 1.16
Compound Leverage Factor		 0.00 1.05 1.08 1.17 1.26 1.15 1.14 0.85 0.77 1.12
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 -8.00 -20.07 -1.73 -3.02 -8.42 -5.87 83.38
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 15.88 7.06 5.98 3.62 10.92 7.07 6.17 3.54 12.98
Quick Ratio		 0.00 15.67 6.95 5.79 3.41 10.56 6.79 5.58 3.10 10.49
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -6.79 -5.11 -9.53 -3.83 -13 -8.66 -28 8.07 -15
Operating Cash Flow to CapEx		 -320,194.76% -21,008.56% -10,427.77% -19,246.51% -32,637.08% 0.00% -15,239.72% -270,286.55% -62,611.02% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.03 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.27 1.94 0.00 0.20 0.00 0.00
Accounts Payable Turnover		 0.00 0.27 0.15 0.13 0.15 0.16 0.09 0.06 0.05 0.04
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 74,809.91 12,020.88 0.00 144,326.58 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 1,346.63 2,422.10 2,779.57 2,485.91 2,234.13 3,904.82 5,622.11 6,923.69 10,402.09
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 72,324.00 9,786.75 0.00 138,704.47 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 1.39 0.63 1.50 -1.41 1.77 0.46 20 0.77 6.08
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.19 0.28 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 1.39 -0.76 0.87 -2.92 3.18 -1.31 19 -19 5.30
Enterprise Value (EV)		 0.00 0.00 0.00 1.63 11 1.35 -2.80 0.69 65 336
Market Capitalization		 0.00 0.00 0.00 12 17 22 21 11 74 357
Book Value per Share		 $0.00 $0.03 $0.02 $0.02 $0.01 $0.02 $0.01 $0.01 $0.00 $0.01
Tangible Book Value per Share		 $0.00 $0.03 $0.02 $0.02 $0.01 $0.02 $0.01 $0.01 $0.00 $0.01
Total Capital		 0.00 18 12 12 4.94 23 24 30 9.21 28
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -17 -11 -10 -6.36 -21 -24 -11 -8.44 -22
Capital Expenditures (CapEx)		 0.00 0.02 0.05 0.00 0.01 0.00 0.06 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 1.36 0.57 1.49 -1.43 1.73 0.36 4.59 0.68 6.03
Debt-free Net Working Capital (DFNWC)		 0.00 18 12 12 4.92 23 24 15 9.12 28
Net Working Capital (NWC)		 0.00 18 12 12 4.92 23 24 15 9.12 28
Net Nonoperating Expense (NNE)		 -1.21 0.40 0.25 -0.06 2.56 1.24 -1.10 0.55 1.73 -1.26
Net Nonoperating Obligations (NNO)		 0.00 -17 -11 -10 -6.36 -21 -24 -11 -8.44 -22
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% -17,269.32% 3,504.26% 0.00% 40,192.42% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 59,269.98% 46,232.89% 0.00% 132,168.20% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 59,269.98% 46,232.89% 0.00% 132,168.20% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($20.00) ($15.00) ($9.00) ($5.30) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 53.39M 86.08M 103.74M 208.40M 240.69M 2.43B 3.65B 6.40B
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($15.50) ($20.00) ($15.00) ($9.00) ($5.30) $0.00 $0.00 ($0.12)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 53.39M 86.08M 103.74M 208.40M 240.69M 2.44B 5.25B 6.40B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($20.00) ($15.00) ($9.00) ($5.30) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 53.39M 61.58M 89.49M 169.69M 240.60M 2.44B 5.25B 9.13B
Normalized Net Operating Profit after Tax (NOPAT)		 -7.00 -5.40 -5.88 -8.65 -6.74 -10 -9.97 -8.65 -11 -9.25
Normalized NOPAT Margin		 -6,546.01% 0.00% 0.00% 0.00% -81,149.02% -20,763.92% 0.00% -75,724.69% 0.00% 0.00%
Pre Tax Income Margin		 -5,418.28% 0.00% 0.00% 0.00% -111,991.54% -23,266.43% 0.00% -79,895.68% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -2.12% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -22.84%

Quarterly Metrics And Ratios for Alterity Therapeutics

No quarterly metrics and ratios for Alterity Therapeutics are available.


Financials Breakdown Chart

Alterity Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Alterity Therapeutics' financial year ends in June. Their financial year 2025 ended on June 30, 2025.

Alterity Therapeutics' net income appears to be on an upward trend, with a most recent value of -$7.98 million in 2025, rising from -$5.80 million in 2016. The previous period was -$12.77 million in 2024. View Alterity Therapeutics' forecast to see where analysts expect Alterity Therapeutics to go next.

Alterity Therapeutics' total operating income in 2025 was -$13.21 million, based on the following breakdown:
  • Total Gross Profit: -$83.82 thousand
  • Total Operating Expenses: $13.13 million

Over the last 9 years, Alterity Therapeutics' total revenue changed from $107.01 thousand in 2016 to $0.00 in 2025, a change of -100.0%.

Alterity Therapeutics' total liabilities were at $2.38 million at the end of 2025, a 34.3% decrease from 2024, and a 94.8% increase since 2017.

In the past 8 years, Alterity Therapeutics' cash and equivalents has ranged from $6.36 million in 2020 to $24.03 million in 2022, and is currently $21.80 million as of their latest financial filing in 2025.

Over the last 9 years, Alterity Therapeutics' book value per share changed from 0.00 in 2016 to 0.01 in 2025, a change of 0.5%.


Related Companies

Financial statements for NASDAQ:ATHE last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The comeback story of the century (ticker inside)
In 2013, this struggling PC maker went private amid skepticism from Forbes and the New York Times. Instead of ...
InvestorPlace | Sponsoredtc pixel
The pact that ran the world and dollar just expired
In 1974, a U.S.-Saudi deal tied oil sales exclusively to dollars, forcing nations worldwide to hold dollars an...
Golden Portfolio | Sponsoredtc pixel
Universal basic income is not impossible. It exist (kind of)
Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...
Freedom Financial | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
This tiny piece of glass could be bigger than GPUs
Jensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capita...
Brownstone Research | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
The 90%-off options that empty accounts
A call that cost $3.00 last month now trades for $0.30 - a 90% discount that looks tempting. It's not a bar...
Profits Run | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel